AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: As presented, icaritin showed inhibition on PI3K/AKT and ERK pathway in both AML and CML cells; suppression on JAK/STAT3 in CML, MM, and ENKL cells; and activation on MAPK/JNK in CML and MM cells (Figure 1).